Oligoribonucleotide derivatives for specific inhibition of...

Details Oligoribonucleotide derivatives for specific inhibition of... Oligoribonucleotide derivatives for specific inhibition of...

2005-09-22

2009-12-22

Zara, Jane (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S006120, C435S091100, C435S455000, C536S023100, C536S024300, C536S025200, C536S025300

Reexamination Certificate

active

07635769

ABSTRACT:
The present invention relates to oligoribonucleotide derivatives which have a 2′5′-linked oligoribonucleotide residue without a 5′-phosphate residue on the 3′ end and to the use thereof for specific inhibition of gene expression.

REFERENCES:
patent: 5886165 (1999-03-01), Kandimalla et al.
patent: 2087818 (1993-07-01), None
patent: 0552766 (1993-01-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Chirila, T., et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Crooke, S., Annu. Rev. Med., vol. 55, pp. 61-95 (2004).
Opalinska, J.B. et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Branch, A., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Torrence, P.F. et al., Proc. Natl. Acad. Sci., vol. 90, pp. 1300-1304 (1993).
Froehler, B. et al., Triple-Helix Formation by Oligodeoxynucleotides Containing the Carbocyclic Analogs of Thymidine and 5-Methyl-2′-deoxycytidine,J. Am. Chem. Soc. vol. 114 (1992) pp. 8320-8322.
Bass, B.L., The Short Answer,Nature, vol. 411, May 24, 2001, pp. 428-429.
Jaffe, E. et al., Culture of Human Endothelial Cells Derived From Umbilical Veins,Journal of Clinical Investigation, vol. 52, Nvo. (1973) pp. 2745-2756.
Stirchak, E. et al., Uncharged Stereoregular Nucleic Acid Analogs: 2. Morphoiino Nucieoside Oligometers With Carbamate Internucleoside Linkages,Nucleic Acids Research, vol. 17, No. 15 (1989) pp. 6129-6141.
Uhlmann, E. et al., Antisense Oligonucleotides: A New Therapeutic Principle,Chemical Reviews, vol. 90, No. 4, (Jun. 1990) pp. 543-584.
Uhlmann, E. et al., Oligonucleotide Analogs Containing Dephospho-Internucleoside Linkages, Methods in Molecular Biology, vol. 20,Protocols for Oligonucleotides and Analogs(1993) Chapter 16, pp. 355-389.
Uhlmann, E. et al., Synthesis and Properties of PNA/DNA Chimeras,Angew. Chem. Int. Ed. Engl., vol. 35 (1996) pp. 2632-2638.
Vandendriessche, F. et al., Acyclic Oligonucleotides: Possibilities and Limitations,Tetrahedron, vol. 49, No. 33 (1993) pp. 7223-7238.
Hunziker, J. et al., Nucleic Acid Analogues: Synthesis and Properties,Institute for Organic Chemistry, pp. 331-417.
Engels, J.W. et al., Chemistry of Oligonucleotides,Pharmaceuticals Aspects of Oligonucleotides(2000) pp. 35-78.
Koga, M. et al., Alternating alpha, Beta-Oligothymidylaes With Alternating (3′-3′)- and (5′-5′) Internucleotidic Phosphodiester Linkages As Models for Antisense Oligodeoxyribonucleotides,Journal of Organic Chemistry, vol. 56, No. 12 (Jun. 7, 1991) pp. 3757-3759.
Manoharan, M. 2′-Carbohydrate Modifications in Antisense Oligonucleotide Therapy: Importance of Conformation, Configuration and Conjugation,Biochimica et Biophysica, Actavol. 1489 (1999) pp. 117-130.
Player, M.R. et al., The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation,Pharmacol Ther. vol. 78, No. 2 (1998) pp. 55-113.
Tarkoy, M. et al., Nucleic-Acid Analogues with Constraint Conformational Flexibility in the Sugar-Phosphate Backbone (‘Bycyclo-DNA’),Helvetica Chimca Acta, vol. 76 (1993) pp. 481-510.
Weiner, N. et al., Liposomes As A Drug Delivery System,Drug Development and Industrial Pharmacy, vol. 15, No. 10 (1989) pp. 1523-1554.
Herdewijn, P., Conformationally Restricted Carbohydrate-Modified Nucleic Acids and Antisense Technology,Biochimica et Biophysica Acta, vol. 1489 (1999) pp. 167-179.
Herdewijn, P., Heterocyclic Modifications of Oligonucleotides and Antisense Technology,Antisense&Nucleic Acid Drug Development, vol. 10 (2000) pp. 297-310.
Nielsen, P. et al., Peptide Nucleic Acid (PNA). A DNA Mimic With A Peptide Backbone,Bioconjugate Chem. (1994) vol. 5, pp. 3-7.
Torrence, P. et al., Targeting RNA for Degradation With a (2′-5′)oligodenylate-antisense Chimera,Proc. Natl. Acad. Sci. USA, vol. 90 (Feb. 1993) pp. 1300-1304.
Torrence, P.F. et al., Development of 2′,5′-Oligonucleotides as Potential Therapeutic Agents,Current Medicinal Chemistry, vol. 1 (1994) pp. 176-191.
Iyler, R. et al., Modified Oligonucleotides—Synthesis, Properties and Applications,Curr. Opin. In Molecular Therapeutics, vol. 1, No. 3 (1999) pp. 344-358.
Hayashi, S-I. et al., In Vivo Transfer of Gene and Oligodeoxynucleotides Into Skin of Fetal Rats by Incubation in Amniotic Fluid,Gene Therapy, vol. 3 (1996) pp. 878-885.
Verma, S. et al., Modified Oligonucleotides: Synthesis and Strategy for Users,Annu. Rev. Biochem., vol. 67 (1998) pp. 99-134.
Singh, S.K. et al., LNA (locked nucleic acids): Synthesis and High-Affinity Nucleic Acid Recognition,Chem. Commun. (1998) pp. 1247-1248.
Woolf, T. et al., Specificity of Antisense Oligonucleotides in vivo,Proc. Natl. Acad. Sci, USA. vol. 89 (Aug. 1991) pp. 7305-7309.
Leaman et al., Controlling Gene Expression with 2-5A Antisense, Methods: A Comparison to Methods in Enzymology, vol. 18, No. 3, (Jul. 1999) pp. 252-265.
Kandimalla et al., “Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2′-5′-ribo- and 3′-5′deoxyribonucleotide segments”,Nucleic Acids Research, vol. 25, No. 2 (1997) pp. 370-378.
Torrence et al., Oligonucleotide Structural Parameters That Influence Binding of 5′-O-Triphosphoadenylyl-(2′-5′)-adenylyl—(2′-5′)-adenosine to the 5′-O-Triphosphoadenylyl-(2′-5′)-adenylyl—(2′-5′)-adenosine Dependent Endoribonuclease: Chain Length????, J. Med. Chem., vol. 27, pp. 726-733 (1984).
Summerton et al., Morpholino Antisense Oligomers, Antisense & Nucleic Acid Drug Development, 7, 187-195, 1997.

Affiliated with

Also associated with

Rating

Oligoribonucleotide derivatives for specific inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligoribonucleotide derivatives for specific inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotide derivatives for specific inhibition of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4146755